HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast

HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to
                                  be Webcast

PR Newswire

FRAMINGHAM, Mass. and SYDNEY, Dec. 6, 2012

FRAMINGHAM, Mass. and SYDNEY, Dec. 6, 2012 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less
invasive, miniaturized circulatory support technologies that are
revolutionizing the treatment of advanced heart failure, today announced that
CEO Doug Godshall is scheduled to present at the Oppenheimer 23^rd Annual
Healthcare Conference at 10:00 a.m. EST on Thursday, December 13, 2012.  The
conference is being held December 12-13 at the Waldorf-Astoria in New York
City.

A live webcast of the Company's presentation at the conference will be
available via a link provided at www.heartware.com.  A replay of the webcast
will be available for 90 days at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable
heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure. The HeartWare^® Ventricular Assist
System features the HVAD^® pump, a small full-support circulatory assist
device designed to be implanted next to the heart, avoiding the abdominal
surgery generally required to implant competing devices. The HeartWare System
is approved in the United States for the intended use as a bridge to cardiac
transplantation in patients who are at risk of death from refractory end-stage
left ventricular heart failure, and has received CE Marking in the European
Union and has been used to treat patients in 27 international countries. The
device is also currently the subject of a U.S. clinical trial for destination
therapy. For additional information, please visit the Company's website at
www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000^® and its
securities are publicly traded on The NASDAQ Stock Market and the Australian
Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of
HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.

Website: http://www.heartware.com